DelveInsight's CD-19 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...
Alexion Pharmaceuticals, AstraZeneca’s rare disease unit, shined a light on neuromyelitis optica spectrum disorder (NMOSD), a severe neurological disease, in a short film that debuted Thursday. While ...
– First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks – – First ...
"Multi-center randomized controlled trials with large samples will further confirm the association between vitamin D and NMOSD. It may be necessary for doctors to assess the vitamin D levels of ...
Malignancies and autoimmune diseases do not significantly increase the annualized relapse rate in NMOSD patients within 3 years post-diagnosis. NMOSD patients, however, have a nearly 6 times greater ...
Please provide your email address to receive an email when new articles are posted on . A chart review included 14 adults with NMOSD who switched from rituximab to inebilizumab. No attacks were ...
The US Food and Drug Administration (FDA) has approved the humanized monoclonal antibody eculizumab (Soliris, Alexion Pharmaceuticals) for the treatment of neuromyelitis optica spectrum disorder ...
Enspryng lowered relapse severity in double-blind periods of SAkura Phase III studies (SAkuraSky, SAkuraStar). Pooled data from SAkura open-label extension (OLE) studies support continued effect of ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results